Osimertinib Not Yet Recruiting Phase 2 Trials for Lung Cancers Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02824952Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC